Integrating molecular diagnostics into anticancer drug discovery.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Trastuzumab, an HER2-targeted therapy, was approved using HER2 expression for patient selection.
• This success influenced the development of drugs targeting the epidermal growth factor receptor (EGFR).

Purpose of the Study:

• To analyze the lessons learned from developing EGFR-targeted therapies.
• To discuss strategies for improving anticancer drug discovery by integrating molecular diagnostics.

Main Methods:

• Review of clinical trial data for HER2- and EGFR-targeted therapies.
• Analysis of biomarker utility in patient selection for cancer drugs.

Main Results:

• EGFR expression is an insufficient biomarker for selecting patients for EGFR-targeted therapies in lung and colon cancer.
• Specific mutations within the targeted pathway have been validated as reliable predictors of response.

Conclusions:

• Relying solely on protein expression levels as biomarkers for targeted cancer therapies can lead to clinical development failures.
• Integrating molecular diagnostics, particularly mutation analysis, is crucial for effective patient selection and successful anticancer drug discovery.